CFB-b Human

Complement Factor B Fragment b Human
Shipped with Ice Packs
In Stock

Description

Functional Role in the Complement System

Bb’s primary role is as a subunit of the C3 convertase (C3bBb), which amplifies complement activation by cleaving C3 into C3a (anaphylatoxin) and C3b (opsonin) . Subsequent binding of a second C3b molecule converts the C3 convertase into the C5 convertase (C3bBbC3b), initiating terminal pathway activation and membrane attack complex (MAC) formation .

Critical Steps Involving Bb:

StepMolecular EventOutcome
C3 cleavageBb in C3bBb cleaves C3 → C3a/C3bAmplifies opsonization and inflammation
C5 convertase formationC3bBb binds C3b → C3bBbC3bInitiates MAC assembly and cell lysis
Feedback loopC3bBb generates more C3bSustains alternative pathway activation

Clinical and Pathological Implications

Dysregulation of Bb activity is linked to autoimmune, inflammatory, and metabolic disorders.

Disease Associations:

ConditionMechanism Involving BbDiagnostic Biomarkers
Atypical Hemolytic Uremic Syndrome (aHUS)Uncontrolled Bb-driven C3 convertase activityLow CFB antigen levels, elevated C3a
Systemic Lupus Erythematosus (SLE)Chronic Bb activation → immune complex depositionLow C3, elevated CFB
Age-related Macular Degeneration (AMD)Complement dysregulation in retinal tissueCFB polymorphisms (e.g., rs641153)
Metabolic SyndromeBb-driven adipose tissue inflammation → insulin resistanceElevated CFB in adipose tissue

Metabolic Syndrome: CFB/Bb is implicated in adipose tissue dysfunction. In spontaneously hypertensive rats, Cfb knockout reduced blood pressure, improved glucose tolerance, and redistributed fat from visceral to subcutaneous depots . Human GWAS data link CFB variants to visceral fat, hypertension, and triglycerides .

Targeting Bb in Disease

Therapeutic ApproachTargetDisease ApplicationOutcome
IptacopanCFB/Bb inhibitionPNH, IgAN, C3 glomerulopathyReduced hemolysis, proteinuria
siRNA (GalXC-CFB)Hepatic CFB knockdownRheumatoid ArthritisReduced synovial C3/CFB, cartilage erosion
Monoclonal AntibodiesBb neutralizationAMD, aHUSPreclinical models show efficacy

Rheumatoid Arthritis (RA): Bb is elevated in RA synovial fluid. siRNA targeting CFB reduced immune cell infiltration and joint damage in murine models .

Genetic and Epigenetic Insights

Genetic VariantAssociationClinical Relevance
rs641153 (CFB)AMD, pancreatic cancer prognosisImpaired complement regulation
Cis-eQTLs at CFBVisceral fat, hypertensionAltered CFB expression linked to MetS

Diagnostic and Analytical Methods

MethodPrincipleApplications
ELISASandwich assay for CFB antigenQuantify CFB levels in serum/plasma
AH50 AssayMeasures alternative pathway activityDiagnose CFB deficiency (e.g., aHUS)
Flow CytometryBb binding to C3b-coated surfacesAssess convertase formation
SPR (Surface Plasmon Resonance)Real-time Bb-C3b kineticsStudy binding affinity and allosteric regulation

Limitations: Direct Bb measurement is challenging; most assays infer activity via CFB levels or pathway function.

References

Product Specs

Introduction
Complement Factor B, also known as CFB, encodes complement factor B, a component of the complement system's alternative pathway. Factor B, circulating in the blood as a single-chain polypeptide, is cleaved by complement factor D upon alternative pathway activation. This cleavage yields the noncatalytic chain Ba and the catalytic subunit Bb. Bb, a serine protease, binds to C3b, forming the alternative pathway C3 convertase. Additionally, Bb participates in preactivated B lymphocyte proliferation, while Ba inhibits it.
Description
Human CFB-b, with a molecular mass of 33 kDa, produced in human plasma.
Physical Appearance
Sterile filtered solution.
Formulation
CFB-b solution (1mg/ml) is prepared in phosphate-buffered saline at pH 7.3.
Stability
CFB-b Human remains stable at 4°C for 2-4 weeks, provided the entire vial is used within this period. For extended storage, freeze below -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity
Purity exceeds 95.0% as determined by SDS-PAGE.
Human Virus Test
Plasma from all donors has undergone testing and is confirmed negative for antibodies against HIV-1, HIV-2, HCV, and HBSAG.
Synonyms

Complement factor B (EC:3.4.21.47), C3/C5 convertase, Glycine-rich beta glycoprotein, GBG, PBF2, Properdin factor B, Complement factor B Ba fragment, Complement factor B Bb fragment, CFB, Complement Factor B, BFD, AHUS4, BF, BFD, CFAB, FB, FBI12, H2-Bf.

Source

Human Plasma.

Product Science Overview

Structure and Function

Complement Factor B is a glycosylated protein composed of a single polypeptide chain with a molecular weight of approximately 93,000 Da . It is found in plasma at a concentration of around 200 µg/mL . Upon activation by Factor D, Complement Factor B is cleaved into two fragments: Ba and Bb . The Bb fragment, which is the focus of this article, is a serine protease with a molecular weight of approximately 60,000 Da .

The Bb fragment is essential for the formation of the C3 and C5 convertases, which are crucial for the activation of the complement system . Specifically, Bb combines with Complement Factor 3b (C3b) to form the C3b,Bb complex, which acts as a C3 convertase. This complex can further bind another C3b molecule to form the C5 convertase, which is responsible for cleaving C5 into C5a and C5b .

Biological Activities

The Bb fragment has been implicated in various biological activities, including:

  • Proliferation and Differentiation of B-Lymphocytes: Bb has been shown to stimulate the proliferation and differentiation of preactivated B-lymphocytes .
  • Monocyte Activation: Bb promotes the rapid spreading of peripheral blood monocytes .
  • Lymphocyte Blastogenesis: Bb stimulates lymphocyte blastogenesis, which is the process of lymphocyte activation and proliferation .
  • Erythrocyte Lysis: Bb can induce the lysis of erythrocytes .
Preparation and Purification

Complement Factor B and its fragments are typically purified from normal human serum. The purification process involves several steps to ensure the protein’s integrity and activity. Factor B is first isolated from the serum, and then it is activated by Factor D to produce the Ba and Bb fragments . The Bb fragment is then further purified to remove any contaminants and ensure its purity .

Clinical Significance

Deficiencies or dysregulations in Complement Factor B can lead to various immunological disorders. For example, Complement Factor B deficiency (CFBD) is characterized by increased susceptibility to bacterial infections, particularly Neisseria infections . This condition arises due to a defect in the alternative complement pathway, which impairs the body’s ability to effectively clear pathogens .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.